ASCO Annual Meeting: Breast Cancer

Although the results from persevERA were not statistically significant, they may support using oral SERDs for patients with ER+/HER2– breast cancer.

Data from the phase 3 SENOMAC trial showed that omitting completion ALND led to non-inferior 5-year OS and lower arm morbidity for patients with breast cancer.

GLP-1 receptor agonist use was tied to reduced HR+/HER2− breast cancer incidence and improved overall survival in nondiabetic women with elevated BMI.

First-line sacitizumab govitecan plus pembrolizumab prolonged PFS2 PD-L1+ metastatic triple-negative breast cancer.

Patients with breast cancer experienced improvement in vasomotor symptoms when treated with elinzanetant, irrespective of type of endocrine therapy.

Switching to camizestrant plus CDK4/6i upon ESR1 mutation detection demonstrated a PFS of 7.6 months and achieved significant PFS2 benefit in SERENA-6.

Giredestrant plus palbociclib improved PFS numerically but not significantly vs letrozole plus palbociclib in 1L ER+, HER2– mBC.

Findings from the I-SPY 2.2 trial may show an important step toward treatment de-escalation for certain patients with HER2-negative breast cancer.

Data from the VIKTORIA-1 trial support the PAM pathway as a molecular driver in HR-positive, HER2-negative breast cancer of any PIK3CA mutation status.

Data from the PANKU-Breast02 trial may support iza-bren as a new standard of care in this TNBC population.

For patients with early breast cancer receiving chemotherapy, the use of a dexamethasone mouthwash did not significantly reduce the incidence of oral mucositis.

Sacituzumab govitecan plus pembrolizumab maintained PFS improvements vs chemotherapy plus pembrolizumab in first-line metastatic TNBC.

Results from the phase 3 lidERA Breast Cancer trial demonstrated a 35% reduction in the risk of invasive disease or death with giredestrant in this breast cancer population.

The assay may identify a group comprising approximately two-thirds of patients who do not have a meaningful chance of benefit from adjuvant chemotherapy.

Paolo Tarantino, MD, PhD, discussed how clinical aggressiveness, toxicity, and progression patterns guide the sequencing of ADCs in breast cancer care.

Patients with breast cancer and macrometastases who omitted axillary lymph node dissection experienced noninferior survival compared with those who didn’t.

Leading experts preview highly anticipated breast cancer data at ASCO 2026, including readouts from the SERENA-6, persevERA, and OPTIMA trials.

A telephone-based weight loss intervention from the phase 3 BWEL trial improved physical function, fatigue, and social role outcomes vs health education alone in patients with stage II to III breast cancer and BMI of at least 27.

Data from the ELEVATE trial may support elacestrant as an endocrine therapy backbone in ER-positive, HER2-negative metastatic breast cancer.

“Higher pretreatment HER2 amplicon mRNA signature and HER2 protein expression predicted improved outcomes with T-DXd for [metastatic breast cancer],” Paolo Tarantino, MD, PhD, said.

Data from DESTINY-Breast09 may support trastuzumab deruxtecan plus pertuzumab as a frontline standard of care in HER2-positive advanced breast cancer.

Data from the phase 3 NATALEE trial confirms ribociclib plus NSAI consistently improves survival outcomes in stage II/III HR+/HER2– early breast cancer patients, regardless of age or menopausal status.

Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.

The use of chemotherapy trended toward improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.

Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.

Patients who received ipatasertib/fulvestrant in the intention-to-treat population achieved a median PFS of 5.32 months compared with 1.94 months in the placebo arm.

In the phase 3 DESTINY-Breast06 trial, the overall biomarker-evaluable population’s confirmed ORR was 59.4% with T-DXd vs 33.9% with chemotherapy.

Across all 3 treatment arms, global health status/quality of life and functional domains were maintained in the phase 3 EMBER-3 trial.

Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.

PFS was improved with first-line sacituzumab govitecan plus pembrolizumab for patients with PD-L1–positive metastatic TNBC.